Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report
American Journal of Clinical and Experimental Medicine
Volume 2, Issue 5, September 2014, Pages: 103-105
Received: Sep. 24, 2014;
Accepted: Sep. 30, 2014;
Published: Oct. 10, 2014
Views 2963 Downloads 231
Delwar Hossain, Department of Dermatology and Venereology, University of Science and Technology ,Chittagong (USTC), Foy’s Lake, Khulsi, Chittagong, Bangladesh
Follow on us
Three patients had been suffering from benign halo nevus and focal vitiligo. They were treated with topical tacrolimus for 12 months. Remission was achieved in both the diseases. Pigmented moles of the halo nevi were unchanged and no harm was incurred to the patients. There was minimal self-limiting side effect from the tacrolimus.
Benign Halo Nevus, Focal Vitiligo, Treatment, Topical Tacrolimus
To cite this article
Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report, American Journal of Clinical and Experimental Medicine.
Vol. 2, No. 5,
2014, pp. 103-105.
Stierman SC, Tierney EP, Shwayder TA. Halo congenital nevocellular nevi associated with extra lesional vitiligo. A case series with review of the literature. Pediatr Dermatol, 2009; 26: 414-424.
Frank SB and Cohen JH. The halo nevi. Archive Dermatol 1964; 89: 367-73.
Pearl E. Grimes, MD, Teresa Soriano, MD, and Mailene T. Dytoc MD, Ph D. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
William L. Epstein, MD; Richard Sagebeil, MD; Lynn Spitler, MD; Joseph Wybran, MD; William B. Reed, MD; M. Scot Blois. Halo nevi and melanoma. JAMA. 1973; 225(4): 373-377.
Copeman, P. W. M., Lewis, M. G., and Elliott, P. G. Immunological Associations of the Halo Naevus with Cutaneous Malignant Melanoma. Brit. J. Dermatol 1973; 88: 127-137.
Lawrence I. Tacrolimus (FK 506) experience in dermatology. Dermatol Ther 1998; 5: 74-84.